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Abstract
Background: Alpha-thalassemia is the most common human genetic disease worldwide. Copy number variations
in the form of deletions of α-globin genes lead to α-thalassemia while duplications of α-globin genes can cause a
severe phenotype in β-thalassemia carriers due to accentuation of globin chain imbalance. It is important to have
simple and reliable methods to identify unknown or rare deletions and duplications in cases in which thalassemia is
suspected but cannot be confirmed by multiplex gap-PCR. Here we describe a copy number variation assay to
detect deletions and duplications in the α-globin gene cluster (HBA-CNV).
Results: Quantitative real-time PCR was performed using four TaqMan® assays which specifically amplify target
sequences representing both the α-globin genes, the –α3.7 deletion and the HS-40 region. The copy number for
each target was determined by the 2-ΔΔCq method. To validate our method, we compared the HBA-CNV method
with traditional gap-PCR in 108 samples from patients referred to our laboratory for hemoglobinopathy evaluation.
To determine the robustness of the four assays, we analyzed samples with and without deletions diluted to obtain
different DNA concentrations. The HBA-CNV method identified the correct copy numbers in all 108 samples. All four
assays showed the correct copy number within a wide range of DNA concentrations (3.2-100 ng/μL), showing that
it is a robust and reliable method. By using the method in routine diagnostics of hemoglobinopathies we have also
identified several deletions and duplications that are not detected with conventional gap-PCR.
Conclusions: HBA-CNV is able to detect all known large deletions and duplications affecting the α-globin genes,
providing a flexible and simple workflow with rapid and reliable results.
Keywords: α-thalassemia, Copy number variation, Quantitative real-time PCR, α-globin gene cluster, HS-40,
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Background
Copy number variations (CNVs) in the human genome are
important genetic variations where large segments of DNA
(> 1 Kb) are present in a variable number of copies in
comparison to a reference genome [1]. A variety of
processes can result in CNVs, including deletions, du-
plications and translocation during meiosis [1]. CNVs
may influence both mRNA and protein levels and have
recently been associated with several complex and common
diseases [1,2].
Thalassemia is one of the most common human genetic
diseases worldwide and is caused by reduced or absent
production of globin chains, mainly of the α- or β- globin
chains resulting in α- or β-thalassemia, respectively [3].
Most commonly, α-thalassemia is the result of the dele-
tion of one or both of the α-globin genes, HBA1 and
HBA2, located in the telomeric region on chromosome 16
(16p13.3). Point mutations that inactivate one of the linked
α-globin genes are less frequent, but these non-deletional
α-thalassemia variants may give rise to more severe reduc-
tion in α-chain production than deletion of one α-globin
gene [4]. Reciprocal recombination during meiosis have
caused the common -α3.7 and –α4.2 deletions and the
α-globin gene triplications, αααanti3.7 and αααanti4.2 [5]. The
α-globin gene triplications most often have no phenotypic
effect, but co-inheritance of an α-globin gene triplication
and β-thalassemia trait may lead to more pronounced im-
balance between α- and β-globin chains and β-thalassemia
intermedia [6]. Duplication of the complete α-globin gene
cluster has also been identified, increasing the number of
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α-globin genes from 4 to 6 in heterozygotes [7,8]. The
expression of the α-globin genes are mainly regulated by
the erythroid-specific DNase I hypersensitive site HS-40,
located 40 Kb upstream of the sequence encoding the
ζ-globin mRNA cap site [9]. Deletions involving only
the HS-40 region give rise to a particular category of
α-thalassemia with intact but functionally inactive α-globin
genes [9].
Seven of the most common deletions that cause α-
thalassemia (-α3.7, -α4.2, –SEA, –FIL –MED, -(α)20.5 and –THAI)
can easily be detected by multiplex gap-PCR [10,11].
However, there are several α-thalassemia associated dele-
tions that will not be identified with this method [12].
Nor will co-inheritance of α-globin gene triplications in
beta-thalassemia carriers be identified.
Several methods have been developed to identify un-
known deletions and duplications in the α-globin genes,
using quantitative real-time PCR (real-time qPCR) assays
[13-15] or multiplex ligation-dependent probe amplifica-
tion (MLPA) assays [16,17]. Here, we describe a fast, ro-
bust and specific method, designated HBA-CNV, that
measures copy number variation using real-time qPCR.
The method is designed to detect all larger deletions and
duplications affecting the two α-globin genes and the
regulatory region, HS-40.
Results and discussion
Using the genome browser software with the implemented
HbVar track, four positions were chosen for amplification
(Figure 1). A pre-design TaqMan® Copy Numbers Assay
was chosen to detect deletions affecting HBA1. In addition,
three primer pairs and probes were designed to specifically
amplify target sequences representing the HBA2 gene,
the –α3.7 deletion and the HS-40 region. In addition to
novel, larger deletions of the α-globin cluster, this
method was designed to detect all known large deletions
affecting one or both α-globin genes and their regulatory
region causing α-thalassemia.
To evaluate the efficiency of each copy number variation
assay, standard curves were generated using 10-fold serially
diluted DNA samples (a pool of three different samples).
The slope coefficients of the standard curves of the five
reactions (HBA1, HBA2, HBA3.7, HS-40 and RNaseP)
were all between 3.2 and 3.4, indicating a PCR amplification
efficiency of more than 97% (Figure 2). Gel electrophoresis
of all PCR targets excluded the presence of primer dimers
or unspecific PCR products.
A calibrator sample with two copies of both α-globin
genes is necessary for correct determination of copy num-
ber in unknown samples. To achieve this, four random
patient samples showing no deletions in the multiplex
gap-PCR method were amplified with all four CNV assays,
each sample alone and together as a DNA pool. All
samples showed two copies on all four assays (results not
shown). The DNA pool was used as a calibrator sample in
further experiments.
Two-fold serial dilutions of a normal DNA sample
and a DNA sample with a known deletion (αα/–SEA)
were analyzed to determine the robustness of the HBA-
CNV assay. All four assays showed the correct number of
copies in a wide range of DNA template concentrations
(3.2 - 100.0 ng/μL) (Figure 3).
To evaluate the newly developed CNV assays, we com-
pared this method with a conventional gap-PCR detecting
the seven most common α-thalassemia deletions [11] in
108 patient samples (Table 1). The samples comprised
ten different combinations of CNVs in the α-globin region,
including both normal samples and deletions of one, two
and three α-globin genes. With the HBA-CNV method, we
correctly identified 24 one-gene deletions, 18 two-gene
deletions, including eight homozygous –α3.7 deletions, as
well as one three-gene deletion and 63 samples without
any deletion. In addition, we identified two samples with
the α-globin gene triplication αααanti3.7. Calculated copy
numbers by the HBA-CNV analysis are shown in Table 2
for all four assays.
Detection of copy number variations in patients
Since its development and validation, we have used this
newly developed method in routine diagnostics of hemo-
globinopathies when thalassemia is suspected from the
complete blood count but not confirmed by hemoglobin
HPLC or gap-PCR. Several duplications and deletions
undetectable with conventional gap-PCR have been
identified with the new method. As an example, we
found co-inheritance of the αααanti3.7-triplication in a
β-thalassemia carrier with β-thalassemia intermedia pheno-
type (Figure 4A). Heterozygosity for a large duplication of
the complete α-globin gene cluster, including the upstream
regulatory element HS-40, was identified in a β-thalassemia
carrier with severe hemolytic anemia (Figure 4B). The du-
plication was confirmed by MLPA and aCGH. The aCGH
analysis showed that the duplication was approximately
170 kb in size and included the genes NPRL3, HBZ,
HBM, HBA2, HBA1, LUC7 and ITFG3. Patients C and D
in Figure 4 showed reduced MCV and MCH, normal HbA2
and HbF levels and an increased number of erythrocytes.
Conventional gap-PCR was negative for both. The HBA-
CNV assay profile for patient C revealed the presence of a
deletion involving both α-globin genes. For patient D the
HBA-CNV assay profile revealed a deletion of the complete
α-globin gene cluster, including the HS-40 element.
Discussion
Copy number variations in the form of deletions and du-
plications that encompass the α-globin genes can cause α-
thalassemia or a more severe phenotype in β-thalassemia
carriers, respectively. Traditional PCR methods are limited
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to detect known deletions and triplications. However,
there are several cases in which patients show typical
hematological changes indicating thalassemia (increased
erythrocyte count, low MCV and MCH), but have normal
HbA2 and HbF and negative gap-PCR. In such cases, it is
important to have simple and reliable methods to identify
unknown or rare deletions and duplications as part of the
diagnostic armamentarium. With the implementation
of the newly developed method, we were able to detect sev-
eral copy number variations which had remained unidenti-
fied by traditional gap-PCR. The αααanti3.7- triplications
were confirmed using multiplex anti 3.7/4.2 PCR. By using
Figure 1 Location of the four CNV assays. Primers and probes were designed to efficiently amplify specific non-homologous regions in the
α-globin gene cluster at the telomeric end of chromosome 16 (16p13.3). An assay located in intron 7 of the NRPL3 gene detects CNVs in the
HS-40 element, which plays an important role in regulation of the α-globin genes. Black solid lines indicate known large deletions in the α-globin
gene cluster, whereas small, blue dots indicate single nucleotide substitutions and small insertions and deletions that give rise to either
hemoglobin variants or α-thalassemia.
Figure 2 Evaluation of efficiency of each target CNV assay and reference assay RNaseP. Quantification cycle is plotted as a function of
DNA concentration. Standard curves were generated using a 10-fold serial dilution of DNA. The resulting equations were: y = 3,2868x + 36,147,
y = 3.1712x + 35.587, y = 3.3393x + 36.224, y = 3.2791x + 35.417 and y = 3.4487x + 36.523 for the HBA1, HBA2, HBA3.7, HS-40 and Rnase P assays,
respectively. All curves showed a highly linear correlation (r2) of 1.0, 0.999, 0.999, 0.999 and 1.0, respectively.
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MLPA and aCGH we confirmed the duplication of the
complete α-globin gene cluster and estimated the size to
be approximately 170 Kb. Based on the HbVar database
[12], our method can be expected to detect all known
larger deletions and duplications in the α-globin gene
cluster and the DNase I hypersensitive site HS-40, making
it superior to the traditional gap-PCR. The HBA-CNV
method is, however, only able to determine the total num-
ber of copies of the target sequence, not the number on
each allele. As a result, patients with αααanti3.7-triplication
on one allele and -α3.7-deletion on the other allele
(αααanti3.7/-α3.7) will be incorrectly interpreted as αα/αα, if
this method is used alone. The same will happen with the
αααanti4.2/-α4.2 genotype. When the HBA-CNV method is
used as a supplement to multiplex gap-PCR, this limitation
will not affect the interpretation.
In our laboratory, all samples referred for hemoglo-
binopathy evaluation undergo standard evaluation, including
complete blood count, measurement of serum or plasma
ferritin concentrations, HPLC analysis of hemoglobin and
multiplex gap-PCR. In cases where the hematological
changes can not be explained by these standard methods,
HBA-CNV and direct sequencing of the α-globin genes are
performed. The HBA-CNV method and direct sequencing
complement each other as sequencing detects point muta-
tions and small deletions/insertions while HBA-CNV
detects large deletions/insertions that are not revealed
by sequencing. Together, HBA-CNV and direct sequen-
cing thus provide powerful and flexible tools to identify
known and novel thalassemia mutations. Our method is
also useful for screening both common and unknown
deletional α0-thalassemia. According to the guidelines of
the British Committee for Standards in Haematology, an
α-thalassemic status should be considered if the MCH is
below 27 pg in the absence of a hemoglobin variant, β- or
δβ-thalassemia heterozygosity [18]. Deletion of one α-globin
gene (α+-thalassemia) is very common and found in many
ethnic groups. Heterozygous α+-thalassemia is a clinically
very mild form of α-thalassemia with slight microcytosis
or normal hematological findings. Even if inherited in the
homozygous state, α+-thalassemia is of no risk to a fetus
[18]. The guidelines of the British Committee for Standards
in Haematology therefore conclude that “α+ thalassemia is
not regarded as significant in the screening programme and
policies are designed to detect only couples at risk of
hydrops fetalis” [18]. Based on this, one might argue that
using only our HBA1- and HBA2 assay would detect all
clinically relevant α-thalassemic deletions in the setting of
a screening, making our method a rapid, reliable and cost
Figure 3 Robustness of the copy number variation assay. Two-fold serial dilution of a normal DNA sample (black columns) and a DNA
sample with a known deletion (grey colums) were analyzed against a calibrator sample with a total concentration of 20 ng/μL. The assay reported
the correct number of copies in a wide DNA concentration range from 3.2-100 ng/μL. The error bars indicates the minimum and maximum copy
number calculated for each group of replicate sample.
Table 1 Predicted copy number in 108 patient samples
Genotype Samples (n) Copy number predicted
HBA1 HBA3.7 HBA2 HS-40
αα/αα 63 2 2 2 2
-α3.7/αα 22 2 1 2 2
-α4.2/αα 2 2 2 1 2
-α3.7/-α3.7 8 2 0 2 2
–SEA/αα 7 1 1 1 2
–FIL/αα 1 1 1 1 2
-(α)20.5/αα 1 1 1 1 2
–MED/αα 1 1 1 1 2
-α3.7/–SEA 1 1 0 1 2
αα/αααanti3.7 2 2 3 2 2
Total 108
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Table 2 Accuracy and specificity of the HBA-CNV assays
Assay Samples (n) Copy number calculated (mean ± 2SD)
0 copies 1 copy 2 copies 3 copies 0 copy 1 copy 2 copies 3 copies
HBA1 0 10 98 0 N/A 0,92 ± 0,22 1,86 ± 0,37 N/A
HBA3.7 9 32 65 2 0 1,10 ± 0,23 2,00 ± 0,39 2,55 ± 0,07
HBA2 0 13 95 0 N/A 0,90 ± 0,20 1,93 ± 0,47 N/A
HS-40 0 0 65 0 N/A N/A 1,90 ± 0,27 N/A
Figure 4 Copy number variation in patients. A shows data for a patient heterozygous for the α-globin gene triplication αααanti3.7. B shows a
large duplication of the complete α-globin gene cluster. C demonstrates a large deletion affecting both α-globin genes, and D shows a deletion
of the HS-40 region in addition to the two α-globin genes. Control samples and non-template controls are not shown.
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efficient method for screening for heterozygous α0 thalas-
semia, i.e. deletions of both HBA1 and HBA2 on the same
chromosome. Following this strategy, however, the conse-
quences of overlooking an α+ thalassemia or a deletion of
the HS-40 region need to be kept in mind. In combination
with α0-thalassemia such mutations may lead to more
severe forms of α-thalassemia, like HbH disease and
hydrops fetalis, respectively.
SYBR Green real-time qPCR has been used for analysis
of copy number variation in both the α- and β-globin gene
clusters [13,19]. Fallah et al. [13] reported one of the first
assays to detect unknown α-thalassemia deletions based
on the relative, quantitative PCR method using SYBR
Green chemistry. Five primer pairs were designed to
detect CNVs affecting HBA1 and HBA2. Although this
approach saves both time and cost, SYBR Green has
some disadvantages that may play a crucial role when
working with these genes. Because of the large degree of
sequence homology between the genes in the α-globin
gene cluster, assays must have high specificity and sensi-
tivity to obtain reliable results. SYBR Green binds any
double stranded DNA and this lack of specificity may
cause false positive Cq values, and a false negative test re-
sult. The use of hydrolysis probes increases the specificity,
and primer dimers will not influence the analysis. Com-
pared to previously published SYBR Green methods,
our approach enables a more accurate and specific copy
number analysis using the gold standard real-time PCR
TaqMan® probe technology. The same approach has been
used in our laboratory to successfully detect deletions in
the β-globin gene cluster (unpublished data). Zhou et al.
[15] described another qPCR approach based on nested
tailed-primer PCR combined with real-time qPCR. Neither
of the mentioned methods investigate the erythroid-specific
DNase I hypersensitive site HS-40, in which there are
known mutations causing α-thalassemia [9]. By using
only four target CNV assays, our method covers deletions
affecting the important regulatory HS-40 region in addition
to both of the α-globin genes and the common –α3.7 dele-
tion. The target and reference copy number assays are run
in a duplex real-time PCR reaction, and the relative quanti-
fication analysis is performed with CopyCaller™ Software
using a calibrator sample with known copy number of the
target sequence. Our newly developed method determines
0, 1, 2 and 3 gene copies with no overlap in calculated copy
number value within two standard deviations (Table 2).
Real-time qPCR involves less hands-on time and testing
is simple and time-saving compared to conventional PCR
and MLPA.
Conclusion
We have developed a copy number variation analysis for
detection of large deletions and duplications affecting the
two α-globin genes and the regulatory region, HS-40. This
method provides a flexible and simple workflow with rapid
and reliable results.
Methods
Ethylenediaminetetraacetic acid (EDTA) whole blood
samples from patients referred to our laboratory for
hemoglobinopathy evaluation were included. The main
reasons for referral were anemia and/or microcytosis.
The analysis included a complete blood count (Sysmex
XE-2100, Sysmex, Japan), hemoglobin high-performance
liquid chromatography (HPLC) analysis (beta-thalassemia
short program, Variant, Bio-Rad, USA) and serum or plasma
ferritin concentration (Cobas 8000, e602, Roche Diagnostics,
Germany). We used HPLC to identify hemoglobin variants
and to diagnose β-thalassemia trait when HbA2 ≥3.6%.
Genetic testing of the α-globin genes with gap-PCR was
performed in all samples with mean corpuscular volume
(MCV) and/or mean corpuscular hemoglobin (MCH) below
lower reference limit.
DNA extraction
Genomic DNA was prepared from 200 μL EDTA whole
blood using the MagNA Pure LC DNA Isolation Kit I
according to the manufacturer’s instruction (Roche Diag-
nostics, Germany). Genomic DNA was eluted in a final vol-
ume of 100 μL. DNA concentrations were determined
using a Nano Drop ND-1000 Spectrophotometer (Thermo
Scientific, Inc. USA). The DNA was diluted to a final con-
centration of 50 ng/μL prior to conventional PCR and to
10 ng/μL prior to quantitative real-time PCR.
Multiplex gap-PCR
All samples were examined for the seven most common
deletions with multiplex gap-PCR using primers and con-
ditions described elsewhere [11] with a few modifications.
The PCR reaction was performed in a total volume of
25 μL using a Thermal Cycler UNO (VWR, USA). Four μL
of each PCR product was analyzed by electrophoresis using
1.2% FlashGel DNA Cassettes (Lonza, Switzerland) at
200 V for 10 minutes. Pictures were taken with FlashGel
Camera (Lonza).
Multiplex anti 3.7/4.2 PCR
All samples where the new method suggested either
αααanti3.7 and αααanti4.2 were verified with multiplex anti-
3.7 and anti-4.2 PCR as described elsewhere [20] with a few
modifications. The PCR reaction was performed in a total
volume of 25 μL using Thermal Cycler UNO (VWR). Four
μL of each PCR product was analyzed by electrophoresis
using 1.2% FlashGel DNA Cassettes at 200 V for 10 mi-
nutes. Pictures were taken with FlashGel Camera.
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MLPA and aCGH
MLPA (SALSA MLPA Kit P140-B2 HBA, MCR-Holland,
Netherlands) and array-Comparative Genomic Hybridi-
zation (aCGH) (SurePrint G3 Human CGH Microarray
Kit, 180 k, Agilent Technologies, USA) were performed
by the Department of Medical Genetics, Oslo University
Hospital, Ullevaal, using standard settings.
HBA-CNV primer and probe design
We used the HbVar track in the UCSC Genome Browser
[12,21] to design four specific pairs of primers and fluores-
cent hydrolysis probes that would potentially detect all
published large deletions in the α-globin gene cluster. To
detect deletions affecting HBA1, a pre-designed TaqMan®
Copy Numbers Assay, Hs03947236_cn, (Life Technologies,
USA) was used. To detect the common α3.7-deletion and
the αααanti3.7 triplication, a TaqMan® copy number assay
was designed to amplify a 104 bp fragment of the non-
homologous region II of the α-globin gene cluster (forward
primer: 5′-GGCTGTGGGCAGAGTCAGAA-3′ and re-
verse primer 5′-CCCCGTTGGATCTTCTCATTT-3′) to-
gether with a specific TaqMan® FAM™ dye-labeled MGB
probe (5′-TGGCAGACAGGGAGG-3′). Deletions of the
HBA2 gene region and the αααanti4.2 triplication were
identified with specific primers (5′-TCCCCTGCATCCC
TTTCAG-3′ and 5′-GTAATAATCAGTGAGACTGTGG
AA-3′) and a specific TaqMan® FAM™ dye-labeled MGB
probe (5′-CAGTTCATTCAGCTCTG-3′) located in the
non-homologous region I of the α-globin gene cluster,
about 1700 bp upstream of HBA2, amplifying a 109 bp
fragment. To detect copy number variations in the HS-40
region primers were designed to amplify a 101 bp frag-
ment in intron 7 of the NPRL3 gene (specific primers
5′- GCCTCCCCCTCCTGTTTATC-3′, 5′- AGCCTGGC
TGTGAACACTTTG-3′ and TaqMan® FAM™ dye-labeled
MGB probe 5′- AGAGGGAAGGCCATGC-3′). RNase
P was used as a reference gene and was detected by a
pre-designed copy number reference assay with a VIC®
dye-labeled TAMRA™ probe (TaqMan® Copy Number
Reference Assay RNase P, Life Technologies, USA). RNase
P is recommended as the standard reference gene in CNV
experiments [22]. Custom primers and hydrolysis probes
were designed using Primer Express® software, version 1.0
(Life Technologies). Pre-designed and custom assays were
delivered by Life Technologies.
Quantitative real-time PCR
Each of the HBA copy number assays were performed in a
duplex real-time PCR reaction with the TaqMan® Copy
Number Reference Assay for RNase P, using a Viia7 Real-
Time PCR System (Life Technologies) in a standard 96 well
format in a total volume of 20 μl. The PCR was carried out
using 10 μl 2x TaqMan® Universal PCR Master Mix (cat.
no. 4304437, Life Technologies), 1 μl 20x TaqMan® Copy
Number Reference Assay RNase P (Life Technologies), 1 μl
20x TaqMan® Copy Number Assay mix, 6 μl DNase free
water and 2 μl genomic DNA. The final concentration of
genomic DNA was 20 ng/μL in all reactions, except for the
robustness experiments. All samples were amplified in
three replicates and one non-template control per primer
pair was included in each run. In routine diagnostics, two
control samples; a normal DNA sample and a DNA sample
with a known deletion (αα/–SEA), are included in each run
together with a calibrator sample and a non-template con-
trol. The cycling conditions comprised 10 min polymerase
activation at 95°C followed by 40 cycles of 95°C for 15 s
and 60°C for 1 min.
Data analysis
The amplification curves were analyzed using Viia7 RUO
software v1.2 (Life Technologies). To determine the copy
number for the targets in each sample, the real-time PCR
data were exported into the CopyCaller® Software (Life
Technologies). The CopyCaller® software provides the
calculated copy numbers and predicted copy numbers
of each test sample. The software performs a comparative
quantification cycle (Cq) relative quantification on the
real-time data to determine the calculated copy numbers.
First, the difference between the Cq of the target and ref-
erence assay is calculated (ΔCq) in each sample for both
the patient sample and the calibrator sample. Then, the
method compares the ΔCq values of the patient sample
and the calibrator sample (ΔΔCq). With this approach,
the predicted copy number of normal samples with two
copies of each α-globin gene will be 2 for all assays. The
predicted copy number of a sample with one gene deleted
will be 1 in the respective assay, and a sample with a two-
gene deletion will have a predicted copy number of 1 in
all three assays, except for the HS-40 assay. Due to the
mathematics of the 2-ΔΔCq method, the calculated copy
numbers deviates from whole numbers. Predicted copy
numbers are based on the calculated copy numbers and
are specified as whole numbers.
Efficiency
Standard curves to determine the amplification efficiency
were generated using 10-fold serial diluted DNA from a
pool of three different samples. The known concentrations
of these DNA samples were plotted on a logarithmic scale
against the corresponding Cq values. The PCR efficiencies
were calculated according to the slope of the standard
curve and the following equation:
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